Market Research Life Sciences Pharmaceuticals Clinical Trial

Neonatal Encephalopathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $7,500 152 Pages Thelansis Knowledge Partners November, 2021 THKP17066480
Lowest Prices Guaranteed
Price from $7,500
Length 152 Pages
Publisher Thelansis Knowledge Partners
Published Date November, 2021
SKU THKP17066480

Neonatal Encephalopathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Neonatal Encephalopathy Disease overview, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Clinical Trial Landscaping, Probable launch date estimation Regulatory framework, Epidemiology; Incidence, Prevalence, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, the market forecast for the USA, Germany, France, Italy, Spain, UK, Japan and China 2020 to 2030


1. Neonatal Encephalopathy – Key Findings Summary
1.1. Clinical findings
1.1.1. Disease overview
1.1.2. Therapeutic practices
1.1.3. Future outlook
1.2. Commercial findings
1.2.1. Neonatal Encephalopathy market scenario 2020
1.2.2. Neonatal Encephalopathy market scenario 2025
1.2.3. Neonatal Encephalopathy market scenario 2030
2. Neonatal Encephalopathy Overview
2.1. Disease Introduction
2.2. Pathophysiology
2.3. Signs and Symptoms
2.4. Risk Factors
2.5. Etiology
2.6. Classification
2.7. Pathogenesis
2.8. Diagnosis
2.9. Complications
2.10. Treatment Algorithm
2.10.1. Treatment in US (guidelines)
2.10.2. Treatment in EU-5 (guidelines)
2.10.3. Treatment in Japan (guidelines)
2.10.4. Treatment in China (guidelines)
2.11. Treatment Goals for Neonatal Encephalopathy
2.12. Referral Patterns
2.12.1. Referral Scenario in US
2.12.2. Referral Scenario in EU-5
2.12.3. Referral Scenario in Japan
2.12.4. Referral Scenario in China
2.13.Neonatal Encephalopathy Prognosis
2.14.Healthcare burden
2.14.1. Healthcare burden in US
2.14.2. Healthcare burden in EU-5
2.14.3. Healthcare burden in Japan
2.14.4. Healthcare burden in China
2.15. Unmet Needs in Neonatal Encephalopathy management
2.16. Market Opportunity for Neonatal Encephalopathy
2.17. KOL Comments on current and upcoming/expected treatment practices in Neonatal Encephalopathy
3. Epidemiology
3.1. Epidemiology Overview
3.2. Epidemiology by Geography
3.2.1. Neonatal Encephalopathy Epidemiology in US (2019-2030)
3.2.1.1. Incidence of Neonatal Encephalopathy
3.2.1.2. Diagnosed cases
3.2.1.3. Treatable Patient Pool
3.2.1.4. Epidemiology Trends
3.2.2. Neonatal Encephalopathy Epidemiology in EU-5 (2019-2030)
3.2.2.1. Incidence of Neonatal Encephalopathy
3.2.2.2. Diagnosed cases
3.2.2.3. Treatable Patient Pool
3.2.2.4. Epidemiology Trends
3.2.3. Neonatal Encephalopathy Epidemiology in Japan (2019-2030)
3.2.3.1. Incidence of Neonatal Encephalopathy
3.2.3.2. Diagnosed cases
3.2.3.3. Treatable Patient Pool
3.2.3.4. Epidemiology Trends
3.2.4. Neonatal Encephalopathy Epidemiology in China (2019-2030)
3.2.4.1. Incidence of Neonatal Encephalopathy
3.2.4.2. Diagnosed cases
3.2.4.3. Treatable Patient Pool
3.2.4.4. Epidemiology Trends
3.3. Epidemiology Trends (World-wide)
4. Market Outlook
4.1. US Neonatal Encephalopathy Market Forecast 2019-2030
4.1.1. Market Progression (Futuristic)
4.1.2. Market Trends and Expectations
4.1.2.1. Worst case scenario
4.1.2.2. Base Case Scenario
4.1.2.3. Best Case Scenario
4.1.3. Drivers and Barriers
4.2. UK Neonatal Encephalopathy Market Forecast 2019-2030
4.2.1. Market Progression (Futuristic)
4.2.2. Market Trends and Expectations
4.2.2.1. Worst case scenario
4.2.2.2. Base Case Scenario
4.2.2.3. Best Case Scenario
4.2.3. Drivers and Barriers
4.3. France Neonatal Encephalopathy Market Forecast 2019-2030
4.3.1. Market Progression (Futuristic)
4.3.2. Market Trends and Expectations
4.3.2.1. Worst case scenario
4.3.2.2. Base Case Scenario
4.3.2.3. Best Case Scenario
4.3.3. Drivers and Barriers
4.4. Germany Neonatal Encephalopathy Market Forecast 2019-2030
4.4.1. Market Progression (Futuristic)
4.4.2. Market Trends and Expectations
4.4.2.1. Worst case scenario
4.4.2.2. Base Case Scenario
4.4.2.3. Best Case Scenario
4.4.3. Drivers and Barriers
4.5. Italy Neonatal Encephalopathy Market Forecast 2019-2030
4.5.1. Market Progression (Futuristic)
4.5.2. Market Trends and Expectations
4.5.2.1. Worst case scenario
4.5.2.2. Base Case Scenario
4.5.2.3. Best Case Scenario
4.5.3. Drivers and Barriers
4.6. Spain Neonatal Encephalopathy Market Forecast 2019-2030
4.6.1. Market Progression (Futuristic)
4.6.2. Market Trends and Expectations
4.6.2.1. Worst case scenario
4.6.2.2. Base Case Scenario
4.6.2.3. Best Case Scenario
4.6.3. Drivers and Barriers
4.7. Japan Neonatal Encephalopathy Market Forecast 2019-2030
4.7.1. Market Progression (Futuristic)
4.7.2. Market Trends and Expectations
4.7.2.1. Worst case scenario
4.7.2.2. Base Case Scenario
4.7.2.3. Best Case Scenario
4.7.3. Drivers and Barriers
4.8. China Neonatal Encephalopathy Market Forecast 2019-2030
4.8.1. Market Progression (Futuristic)
4.8.2. Market Trends and Expectations
4.8.2.1. Worst case scenario
4.8.2.2. Base Case Scenario
4.8.2.3. Best Case Scenario
4.8.3. Drivers and Barriers
4.9. Key Expected Milestones (world-wide) Impacting the Market
5. Competitive Landscape
5.1. Pipeline Therapies Overview
5.1.1. Phase III Therapies
5.1.1.1. Current Status
5.1.1.2. Trial details, results
5.1.1.3. Approval Timeline
5.1.1.4. Likelihood of approval
5.1.1.5. Expected Product Positioning
5.1.1.2. All other Phase III Therapies …..
5.1.1.3. Attribute Analysis of Phase III molecules
5.1.2. Phase II and Phase I/II Therapies
5.1.2.1. Current Status
5.1.2.2. Trial details, results
5.1.2.3. Approval Timelines
5.1.3. List of active Pre-clinical Therapies
5.1.3.1. Status in Neonatal Encephalopathy
5.1.3.2. Company positioning
5.1.3.2. All other pre-clinical therapies
5.1.4. List of Inactive/discontinued assets
5.1.4.1. Business impact of discontinuations on current pipeline
5.1.5. Potential winners from Neonatal Encephalopathy Pipeline
5.1.5.1. Potential Blockbusters across the pipeline
6. Regulatory/Approval Scenario
6.1. Regulatory/Approval Framework in US
6.1.1. Policy Framework
6.1.2. Payer Expectations
6.2. Regulatory/Approval Framework in UK
6.2.1. Policy Framework
6.2.2. Payer Expectations
6.3. Regulatory/Approval Framework in France
6.3.1. Policy Framework
6.3.2. Payer Expectations
6.4. Regulatory/Approval Framework in Germany
6.4.1. Policy Framework
6.4.2. Payer Expectations
6.5. Regulatory/Approval Framework in Italy
6.5.1. Policy Framework
6.5.2. Payer Expectations
6.6. Regulatory/Approval Framework in Spain
6.6.1. Policy Framework
6.6.2. Payer Expectations
6.7. Regulatory/Approval Framework in Japan
6.7.1. Policy Framework
6.7.2. Payer Expectations
6.8. Regulatory/Approval Framework in China
6.8.1. Policy Framework
6.8.2. Payer Expectations
7. Clinical Trial Assessment – Current and Future Paradigm
7.1. Distribution of Primary Endpoints across trials
7.2. Distribution of Secondary Endpoints across trials
7.3. Evolution and acceptance of surrogate endpoints
7.4. Key Investigator initiated trials
7.5. Attrition analysis
7.5.1. Suspended/Discontinued Assets
7.5.2. Failed Trials, Reasons and Business Impact
7.5.3. Terminated Trials, Reasons and Business Impact
7.5.4. Withdrawn Trials, Reasons and Business Impact
7.6. Trial enrollment scenario and challenges
7.7. Clinical Trial Guidance (across geographies)
8. Thelansis Commentary
8.1. Key Unmet needs in Neonatal Encephalopathy
8.2. Possible Best-case Clinical Trial Strategies
8.3. Possible Best Case Targeted Product Profile (TPP)
8.4. Possible Best-case Market positioning strategies
8.5. Possible Best-case Market Access Strategies
8.6. Possible Best-case LCM Strategies
8.7. Overall View on Neonatal Encephalopathy Market in Dollar Value
9. Report Methodology
9.1. Secondary research
9.2. Primary research
9.3. Data collation
9.4. Insight Generation
10. About Thelansis
10.1. Our Capabilities
10.2. Our Services
10.3. Our Contacts
10.4. Disclaimer

$7,500
$12,500

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings